Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry is Developing a More Profound Understanding of Excipients

This article was originally published in The Gold Sheet

Executive Summary

Deeper understanding of the role of excipients in drug formulations is leading manufacturers and pharmacopoeias to develop new more science-based approaches and standards for them. Variability of excipients should be expected: the key is to know which variables are important - and how to counterbalance them. The flexibility of QbD could play a key role. Compendial tests often do not focus on the critical attributes. USP and EP are working to upgrade their excipient standards. USP <1059> draft is seen as step in the right direction with its offering of functional guidance in a general information chapter. Industry fears the 'non-mandatory' functionality-related tests the EP wants to add to excipient monographs would eventually become mandatory. FDA and IPEC work to unfetter novel excipients. FDA would create an excipient functionality database. Regulatory requirements for excipients could be helpful, but progress is slow. Third-party certification could suffice in the interim, though uptake remains slow.

You may also be interested in...



The Anti-Falsification Directive: Europe’s Answer to Global Supply Chain Threats

The European Union July 1 published its directive on falsified medicines, setting into motion a tightening of Europe’s pharmaceutical supply chain that will for the most part take place over the next 18 months – and that could cost pharmaceutical companies billions of Euros.

The Anti-Falsification Directive: Europe’s Answer to Global Supply Chain Threats

The European Union July 1 published its directive on falsified medicines, setting into motion a tightening of Europe’s pharmaceutical supply chain that will for the most part take place over the next 18 months – and that could cost pharmaceutical companies billions of Euros.

EU Considers Including High-Profile Excipients in Applying GMP to API

Political pressure in the EU puts two in-the-news excipients on EU GMP list.

Latest News
See All
UsernamePublicRestriction

Register

PS000406

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel